Zoetis delivered flat revenue in Q2, missing Wall Street expectations, while its adjusted earnings per share slightly exceeded consensus. The market’s positive reaction was underpinned by management’s acknowledgment of intensifying competitive pressures in key Companion Animal categories and ongoing declines in U.S. veterinary clinic visits. CEO Kristin Peck noted, “Veterinary clinic visits declined across markets, extending a multiyear trend that has occurred alongside price increases that have outpaced broader consumer inflation.” The company highlighted resilience in its Livestock and Diagnostics segments, despite softness within dermatology and parasiticides.
Is now the time to buy ZTS? Find out in our full research report (it’s free for active Edge members).
Zoetis (ZTS) Q2 CY2026 Highlights:
- Revenue: $2.47 billion vs analyst estimates of $2.50 billion (flat year on year, 1.5% miss)
- Adjusted EPS: $1.87 vs analyst estimates of $1.85 (1% beat)
- The company dropped its revenue guidance for the full year to $9.22 billion at the midpoint from $9.82 billion, a 6.1% decrease
- Management lowered its full-year Adjusted EPS guidance to $6.20 at the midpoint, a 10.5% decrease
- Operating Margin: 37.4%, down from 39.1% in the same quarter last year
- Market Capitalization: $30.39 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Zoetis’s Q2 Earnings Call
- Erin Wilson Wright (Morgan Stanley) asked about the timing and impact of targeted price actions and how much conservatism was embedded in the updated guidance for U.S. Companion Animal. CEO Kristin Peck clarified that Zoetis is emphasizing temporary, targeted gross-to-net investments rather than permanent list price changes to protect share.
- Brandon Vazquez (William Blair) sought clarification on gross-to-net pricing strategies and the margin implications for the second half. Peck explained these are deliberate, time-bound actions focused on volume and share, while CFO Wetteny Joseph highlighted FX headwinds as another factor in the revised outlook.
- Michael Ryskin (Bank of America) inquired about the extent of cost controls and SG&A reductions, and whether competitive pressures would persist into next year. Joseph noted that cost actions are already benefiting margins, while Peck suggested that competitive intensity may continue into 2027, with a focus on defending differentiated products.
- David Westenberg (Piper Sandler) questioned how much Q2 weakness was due to market contraction versus competition, and whether rebate strategies were sustainable given contract structures. Joseph responded that both macro and competitive factors were meaningful, while Peck noted contract durations vary but promotional flexibility remains key.
- Christopher Schott (JPMorgan) asked about the duration of price promotions and what would trigger a reduction. Peck said promotions would be dialed back if share stabilizes, and that the company is closely monitoring competitive and macro factors in each product category.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will closely watch (1) stabilization or recovery in U.S. veterinary clinic visits and premium therapy demand, (2) the pace of new product launches in dermatology and diagnostics, and (3) the effectiveness of leadership changes in driving commercial execution. Additionally, the StockStory team will monitor ongoing cost discipline efforts and the competitive landscape for signs of easing promotional activity.
Zoetis currently trades at $73.72, in line with $74.39 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
